Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABAT | P80404 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19860333 | 1.00 | ABAT (0.46) | ABATCYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL15466878 | 1.00 | ABAT (0.46) | ABATCYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL1848855 | 1.00 | ABAT (0.46) | ABATCYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL14791315 | 1.00 | ABAT (0.46) | ABATCYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL698731 | 1.00 | ABAT (0.46) | ABATCYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL698732 | 1.00 | ABAT (0.46) | ABATCYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL698234 | 0.78 | ABAT (0.33) | ABAT | |
| SCHEMBL375674 | 0.78 | — | — | |
| SCHEMBL14211851 | 0.74 | — | — | |
| SCHEMBL15466503 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148449-A1 | Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the Uses Thereof | PURDUE PHARMA L.P. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148449-A1 | Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the Uses Thereof | P2RX4, OPRK1, QDPR | ABAT 1457/4885CYP1A2 979/4885CYP2D6 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.